 |
|
|
|
|
New Insights, Inroads Against Breast, Ovarian Cancers
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 | 4 "The drugs are given orally and it still remains a question as to whether the drugs' benefits will extend beyond this narrow patient population," noted Dr. Eric Weiner, head of ASCO's communication committee and chief of women's cancers at the Dana Farber Cancer Institute in Boston.
"These two studies are very exciting," Marcom said. "It speaks to a really clever understanding of the biology of the cancer."
Two other studies presented at ASCO could represent advances in the treatment of cervical cancer. In one study, led by Dr. Alfonso Duenas-Gonzalez of Mexico's National Cancer Institute, researchers found that adding the chemotherapy drug gemcitabine (Gemzar) to standard chemo and radiation therapy improved both progression-free and overall survival -- but not without notable side effects.
Text Continues Below
And for women diagnosed with early-stage cervical cancer, the more specific and less invasive prognostic indicator called sentinel-nose biopsy appears just as effective as removal of lymph nodes in the pelvis, according to French researchers at George Pompidou European Hospital, Paris. According to the researchers, opting for biopsy rather than lymph node removal should make tracking the disease much less onerous for patients.
More information
There's more on cancer affecting women at the U.S. National Cancer Institute.
Page: << Prev | 1 | 2 | 3 | 4
|
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/1/2009
|
|
SOURCES: P. Kelly Marcom, M.D., breast oncologist, Duke Comprehensive Cancer Center, and director, Duke Hereditary Cancer Clinic, Durham, N.C.; Claudine Isaacs, M.D., medical oncologist, Georgetown's Lombardi Comprehensive Cancer Center, Washington, D.C.; May 31, 2009, news conference with Eric Weiner, M.D., chief, division of women's cancers, Dana Farber Cancer Institute, Boston; Gordon Rustin, M.D., professor, oncology, Mount Vernon Cancer Center, Hertfordshire, U.K., and Joyce O'Shaughnessy, M.D., co-director, Breast Cancer Research Dallas Program at Baylor-Charles A. Sammons Cancer Center; American Society of Clinical Oncology annual meeting, Orlando, Fla.
|
.gif)
